DAEWOONG CO.,LTD
003090 | KO
Overview
Corporate Details
- ISIN(s):
- KR7003090008
- LEI:
- Country:
- South Korea
- Address:
- 경기 성남시 중원구 상대원동 223-23, 성남시
- Website:
- https://www.daewoong.co.kr
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-15 00:00 |
Regulatory Filings
투자판단관련주요경영사항(자회사의 주요경영사항)
|
Korean | 14.9 KB | ||
| 2025-09-05 00:00 |
Regulatory Filings
투자판단관련주요경영사항(자회사의 주요경영사항)
|
Korean | 9.0 KB | ||
| 2025-08-14 00:00 |
Annual Report
[기재정정]사업보고서 (2024.12)
|
Korean | 3.7 MB | ||
| 2025-08-14 00:00 |
Interim / Quarterly Report
반기보고서 (2025.06)
|
Korean | 4.0 MB | ||
| 2025-07-30 00:00 |
Regulatory Filings
투자판단관련주요경영사항(자회사의 주요경영사항)
|
Korean | 9.5 KB | ||
| 2025-06-02 00:00 |
Governance Information
기업지배구조보고서공시
|
Korean | 708.5 KB | ||
| 2025-05-16 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 25.7 KB | ||
| 2025-05-16 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
|
Korean | 162.0 KB | ||
| 2025-05-16 00:00 |
Major Shareholding Notification
최대주주등소유주식변동신고서
|
Korean | 58.0 KB | ||
| 2025-05-15 00:00 |
Major Shareholding Notification
[기재정정]최대주주등소유주식변동신고서
|
Korean | 54.8 KB | ||
| 2025-05-15 00:00 |
Quarterly Report
분기보고서 (2025.03)
|
Korean | 2.1 MB | ||
| 2025-05-14 00:00 |
Major Shareholding Notification
[기재정정]최대주주등소유주식변동신고서
|
Korean | 60.7 KB | ||
| 2025-04-16 00:00 |
Capital/Financing Update
단기차입금증가결정(자회사의 주요경영사항)
|
Korean | 11.5 KB | ||
| 2025-04-02 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.0 KB | ||
| 2025-04-01 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
|
Korean | 62.4 KB |
Automate Your Workflow. Get a real-time feed of all DAEWOONG CO.,LTD filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for DAEWOONG CO.,LTD
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for DAEWOONG CO.,LTD via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Develops novel therapies for eye care, including the first FDA-approved Demodex blepharitis drug.
United States of America
TARS
United States of America
TARS
Develops and sells in vitro diagnostics and research reagents, like antigen tests, globally.
Japan
197A
Japan
197A
Develops and makes affordable generic drugs for cardiovascular & metabolic diseases.
Bulgaria
THQM
Bulgaria
THQM
Develops and manufactures transdermal drug delivery systems like patches, plasters, and OTC products.
South Korea
464280
South Korea
464280
Develops cell therapies for skin regeneration, 3D models for testing, and provides CDMO services.
South Korea
191420
South Korea
191420
United States of America
TLX
Clinical-stage pharma developing novel therapies for cardiovascular and pulmonary diseases.
United States of America
TENX
United States of America
TENX
Developing gene therapy, cellular regeneration & precision medicine for heart disease.
United States of America
TNYA
United States of America
TNYA
A leader in affordable generic drugs and innovative specialty treatments for complex diseases.
Israel
TEVA
Israel
TEVA
Commercializes B-cell therapies like BRIUMVI® for multiple sclerosis & autoimmune diseases.
United States of America
TGTX
United States of America
TGTX